Publisher
Springer Science and Business Media LLC
Reference8 articles.
1. TIME. Drugs that fight cancer. TIME
http://content.time.com/time/covers/0,16641,20010528,00.html
(2001).
2. Cohen, M. H. et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 8, 935–942 (2002).
3. FDA. Drugs@FDA: FDA approved drug products. FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588
(2018).
4. Yam, C. et al. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β. Invest. New Drugs 36, 1103–1109 (2018).
5. Carlisle, B. G. et al. Patient benefit and risk in anticancer drug development: a systematic review of the ixabepilone trial portfolio. medRxiv
https://www.medrxiv.org/content/10.1101/19003467v1
(2019).
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献